Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments: second analysis of a randomised EORTC Melanoma Group trial comparing interferon-α2a (IFNα) and interleukin 2 (IL-2) with or without cisplatin
The aim of this study was to define prognostic factors for survival, and especially for long-term survival in a mature data-set of patients with stage IV melanoma treated within a randomised trial of cytokine-based protocols. Long-term follow-up data on patients enrolled into a European Organization...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
24 April 2002
|
| In: |
European journal of cancer
Year: 2002, Jahrgang: 38, Heft: 11, Pages: 1501-1511 |
| ISSN: | 1879-0852 |
| DOI: | 10.1016/S0959-8049(02)00123-5 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/S0959-8049(02)00123-5 Verlag, lizenzpflichtig, Volltext: http://www.sciencedirect.com/science/article/pii/S0959804902001235 
|
| Verfasserangaben: | U. Keilholz, P. Martus, C.J.A. Punt, W. Kruit, G. Mooser, D. Schadendorf, D. Liénard, R. Dummer, J. Koller, C. Voit, A.M.M. Eggermont |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1738907775 | ||
| 003 | DE-627 | ||
| 005 | 20220819025051.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201117s2002 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S0959-8049(02)00123-5 |2 doi | |
| 035 | |a (DE-627)1738907775 | ||
| 035 | |a (DE-599)KXP1738907775 | ||
| 035 | |a (OCoLC)1341376498 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Keilholz, Ulrich |e VerfasserIn |0 (DE-588)111152324X |0 (DE-627)865593043 |0 (DE-576)161675387 |4 aut | |
| 245 | 1 | 0 | |a Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments |b second analysis of a randomised EORTC Melanoma Group trial comparing interferon-α2a (IFNα) and interleukin 2 (IL-2) with or without cisplatin |c U. Keilholz, P. Martus, C.J.A. Punt, W. Kruit, G. Mooser, D. Schadendorf, D. Liénard, R. Dummer, J. Koller, C. Voit, A.M.M. Eggermont |
| 246 | 3 | 0 | |a alpha two |
| 264 | 1 | |c 24 April 2002 | |
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 17.11.2020 | ||
| 520 | |a The aim of this study was to define prognostic factors for survival, and especially for long-term survival in a mature data-set of patients with stage IV melanoma treated within a randomised trial of cytokine-based protocols. Long-term follow-up data on patients enrolled into a European Organization for Research and Treatment of Cancer (EORTC) trial comparing interferon-α (IFNα) plus interleukin-2 (IL-2) with or without cisplatin were collected. Univariate and multivariate Cox regression analyses wereperformed to define prognostic factors for survival. The characteristics of patients alive at 2 and 5 years after randomisation were compared with the entire cohort using the χ2 test. The minimum potential follow-up of the 131 evaluable patients was 5 years. 18 patients (14%) were alive 2 years after randomisation, and 11 (8%) 5 years after randomisation. Pretreatment performance status (PS), serum lactate dehydrogenase (LDH) and tumour mass were significant predictors for survival, whereas site of metastases and number of sites were non-significant. PS and LDH were the only independent prognostic factors. All except 1 patient alive at 2 and 5 years had a pretreatment PS of 100%, and only three long-term survivors had elevated pretreatment LDH. There was no association between the site of metastases and long-term survival. Response to treatment was a major predictor for long-term survival, whereas addition of cisplatin did not impact upon overall survival probability or on long-term survival. The probability of long-term survival in stage IV melanoma patients after IL-2-based treatments is governed by pretreatment PS, serum LDH and response to treatment. Site of metastases, the basis for the M-subcategories of the new AJCC staging system, was not informative in this study. | ||
| 650 | 4 | |a Cytokines | |
| 650 | 4 | |a IL2 | |
| 650 | 4 | |a Melanoma | |
| 650 | 4 | |a Prognostic factors | |
| 700 | 1 | |a Schadendorf, Dirk |d 1960- |e VerfasserIn |0 (DE-588)11142576X |0 (DE-627)499566076 |0 (DE-576)289702275 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of cancer |d Amsterdam [u.a.] : Elsevier, 1992 |g 38(2002), 11, Seite 1501-1511 |w (DE-627)266883400 |w (DE-600)1468190-0 |w (DE-576)090954173 |x 1879-0852 |7 nnas |a Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments second analysis of a randomised EORTC Melanoma Group trial comparing interferon-α2a (IFNα) and interleukin 2 (IL-2) with or without cisplatin |
| 773 | 1 | 8 | |g volume:38 |g year:2002 |g number:11 |g pages:1501-1511 |g extent:11 |a Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments second analysis of a randomised EORTC Melanoma Group trial comparing interferon-α2a (IFNα) and interleukin 2 (IL-2) with or without cisplatin |
| 856 | 4 | 0 | |u https://doi.org/10.1016/S0959-8049(02)00123-5 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S0959804902001235 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20201117 | ||
| 993 | |a Article | ||
| 994 | |a 2002 | ||
| 998 | |g 11142576X |a Schadendorf, Dirk |m 11142576X:Schadendorf, Dirk |d 50000 |e 50000PS11142576X |k 0/50000/ |p 6 | ||
| 999 | |a KXP-PPN1738907775 |e 3805794290 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"note":["Gesehen am 17.11.2020"],"id":{"eki":["1738907775"],"doi":["10.1016/S0959-8049(02)00123-5"]},"title":[{"subtitle":"second analysis of a randomised EORTC Melanoma Group trial comparing interferon-α2a (IFNα) and interleukin 2 (IL-2) with or without cisplatin","title":"Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments","title_sort":"Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments"}],"recId":"1738907775","language":["eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"origin":[{"dateIssuedDisp":"24 April 2002","dateIssuedKey":"2002"}],"relHost":[{"id":{"issn":["1879-0852"],"eki":["266883400"],"zdb":["1468190-0"]},"title":[{"title":"European journal of cancer","title_sort":"European journal of cancer"}],"disp":"Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments second analysis of a randomised EORTC Melanoma Group trial comparing interferon-α2a (IFNα) and interleukin 2 (IL-2) with or without cisplatinEuropean journal of cancer","note":["Gesehen am 21.03.24","Ungezählte Beil.: Supplement"],"language":["eng"],"type":{"bibl":"periodical","media":"Online-Ressource"},"origin":[{"dateIssuedDisp":"1992-","dateIssuedKey":"1992","publisherPlace":"Amsterdam [u.a.] ; [Erscheinungsort nicht ermittelbar]","publisher":"Elsevier ; Pergamon Press"}],"part":{"year":"2002","extent":"11","pages":"1501-1511","text":"38(2002), 11, Seite 1501-1511","issue":"11","volume":"38"},"recId":"266883400","pubHistory":["28.1992 -"],"titleAlt":[{"title":"EJC online"}],"corporate":[{"role":"isb","display":"European Organization for Research on Treatment of Cancer","roleDisplay":"Herausgebendes Organ"},{"roleDisplay":"Herausgebendes Organ","display":"European Association for Cancer Research","role":"isb"},{"role":"isb","display":"European School of Oncology","roleDisplay":"Herausgebendes Organ"}]}],"person":[{"given":"Ulrich","display":"Keilholz, Ulrich","role":"aut","roleDisplay":"VerfasserIn","family":"Keilholz"},{"family":"Schadendorf","roleDisplay":"VerfasserIn","role":"aut","display":"Schadendorf, Dirk","given":"Dirk"}],"physDesc":[{"extent":"11 S."}],"name":{"displayForm":["U. Keilholz, P. Martus, C.J.A. Punt, W. Kruit, G. Mooser, D. Schadendorf, D. Liénard, R. Dummer, J. Koller, C. Voit, A.M.M. Eggermont"]}} | ||
| SRT | |a KEILHOLZULPROGNOSTIC2420 | ||